<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87408">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01991951</url>
  </required_header>
  <id_info>
    <org_study_id>KUMCEP01</org_study_id>
    <nct_id>NCT01991951</nct_id>
  </id_info>
  <brief_title>Short Term Warfarin Therapy for Radiofrequency Catheter Ablation of Atrial Fibrillation</brief_title>
  <official_title>Prospective Randomized Study of Incidence of Thromboembolic and Bleeding Events According to the Period of Warfarin Use Before and After Catheter Ablation of Paroxysmal Atrial Fibrillation in Low Risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesized that in patients with low CHADS-VASc score (2 or &lt; 2), there is no
      difference in thromboembolic or bleeding events between patients with short term warfarin
      therapy (2 weeks after catheter ablation) and conventional therapy (3 weeks before and 8
      weeks after procedure).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of thromboembolic and bleeding events during 2 months</measure>
    <time_frame>2 months after the procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Short term warfarin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>taking warfarin for only 2 weeks after catheter ablation of atrial fibrillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional therapy arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional warfarin therapy of 3 weeks before and 8 weeks after catheter ablation of AF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <arm_group_label>Short term warfarin group</arm_group_label>
    <arm_group_label>Conventional therapy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with paroxysmal atrial fibrillation who underwent radiofrequency catheter
             ablation

          -  Patients with CHADS-VASc score 2 or less than 2

        Exclusion Criteria:

          -  Patients who do not consent to the study

          -  Permanent or persistent atrial fibrillation

          -  Patients who have underwent prior catheter ablation for atrial fibrillation

          -  CHADS-VASc score more than 2

          -  History of stroke

          -  LVEF &lt;40%

          -  Significant liver or kidney dysfunction

          -  History of major bleeding during warfarin therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jaemin Shim, MD</last_name>
    <phone>82-10-6776-1195</phone>
    <email>jshim@kumc.or.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaemin Shim, MD</last_name>
      <phone>82-10-6776-1195</phone>
      <email>jshim@kumc.or.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 21, 2013</lastchanged_date>
  <firstreceived_date>November 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Young-Hoon Kim</investigator_full_name>
    <investigator_title>Professor of medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
